Drug intelligence / Profile preview

Hitanercept

Development stage: Phase 1
Lead developer: Amgen
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Hitanercept, also known as T0001, is a recombinant fusion protein of the human tumor necrosis factor receptor and Fc fragment (rhTNFR:Fc). Developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., it is based on etanercept and acts as an inhibitor of both TNF-alpha and TNF-beta. By binding to these pro-inflammatory cytokines, Hitanercept prevents them from interacting with their natural receptors, thereby attenuating the inflammatory cascade. It is being investigated for the treatment of autoimmune conditions such as rheumatoid arthritis.

Targets

TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)

Beyond the preview

Go deeper on Hitanercept.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hitanercept.

Explore the full profile